Federal authorities announced on May 9 that emergency-use authorization has been granted for the first antigen test for COVID-19.
Antigen tests detect the presence of the disease, while antibody tests indicate past infection.
Hinton added that the emergency-use approval for the new antigen test doesn’t mean it’s been cleared or approved by the FDA for widespread use, but only for use by authorized laboratories.
The FDA has, in the past, issued emergency-use authorization for another type of active infection test, the polymerase chain reaction (PCR) test, which is a diagnostic technique that detects genetic material from a virus.
“Antigen tests are also important in the overall response against COVID-19, as they can generally be produced at a lower cost than PCR tests, and once multiple manufacturers enter the market, can potentially scale to test millions of Americans per day due to their simpler design, helping our country better identify infection rates closer to real time,” the FDA said in the release.
Former FDA Commissioner Scott Gottlieb, explaining in a CNBC op-ed how antigen tests work, wrote, “One approach is based on the use of antibodies that adhere to parts of the virus that contribute to its symptoms called antigens.
“If virus is present, the antibodies bind to these viral antigens and produce a chemical reaction that signals the presence of an infection.”
Based in San Diego, Quidel specializes in tests for flu, strep, and infectious diseases.
“The EUA for our Sofia 2 SARS Antigen FIA allows us to arm our healthcare workers and first responders with a frontline solution for COVID-19 diagnosis, accelerating the time to diagnosis and potential treatment of COVID-19 for the patient,” the company’s CEO stated.